自身免疫性、遗传性和特发性神经病中的神经束蛋白抗体
该研究采用细胞法检测GBS/CIDP、遗传性和特发性神经病患者对三种神经束蛋白异构体的IgG和IgM反应。结果显示自身免疫性神经病中神经束蛋白抗体频率为14%,显著高于遗传性神经病对照的3%。NF155 IgG4抗体与IVIG抵抗但利妥昔单抗有效的CIDP相关。
要点
- GBS/CIDP患者神经束蛋白抗体阳性率14%,显著高于遗传性神经病对照的3%。
- NF155 IgG4抗体与IVIG抵抗但利妥昔单抗有效的CIDP相关,部分呈GBS样急性起病。
- 识别所有三种神经束蛋白异构体的抗体可能提示严重但可治疗的CIDP。
核心结论
- 自身免疫性神经病中神经束蛋白抗体频率是遗传性神经病对照的4倍。
- 持续性NF155 IgG4反应与对常规治疗抵抗但利妥昔单抗有效的严重CIDP相关。
研究设计与样本
- 研究纳入GBS或CIDP患者59例、遗传性神经病111例、特发性神经病43例。
- 采用细胞法检测血清对NF140、NF155和NF186三种异构体的IgG和IgM反应。
主要发现
- GBS/CIDP组神经束蛋白抗体阳性率为14%(8/59),遗传性神经病对照组为3%(3/111),p=0.01。
- 特发性神经病患者中7%(3/43) also had neurofascin antibodies。
- NF155 IgG4抗体与IVIG抵抗但利妥昔单抗有效的CIDP相关,部分患者呈GBS样急性起病。
- NF186 IgG和IgM对任一异构体的特异性较低。
- 一例识别所有三种神经束蛋白异构体的患者表现为接近闭锁状态的严重CIDP。
临床怎么用
- 对IVIG抵抗的CIDP患者可考虑检测NF155 IgG4抗体,阳性者可能对利妥昔单抗有效。
- 识别所有三种神经束蛋白异构体的抗体可能提示严重但可治疗的神经病。
局限性
- 特发性神经病中神经束蛋白抗体的预后意义及GBS中短暂IgM反应需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To measure the frequency, persistence, isoform specificity, and clinical correlates of neurofascin antibodies in patients with peripheral neuropathies. METHODS: We studied cohorts of patients with Guillain-Barre syndrome (GBS) or chronic inflammatory demyelinating polyneuropathy (CIDP) (n = 59), genetic neuropathy (n = 111), and idiopathic neuropathy (n = 43) for immunoglobulin (Ig) G and IgM responses to 3 neurofascin (NF) isoforms (NF140, NF155, and NF186) using cell-based assays. RESULTS: Neurofascin antibodies were more common in patients with GBS/CIDP (14%, 8 of 59) compared to genetic neuropathy controls (3%, 3 of 111, p = 0.01). Seven percent (3 of 43) of patients with idiopathic neuropathy also had neurofascin antibodies. NF155 IgG4 antibodies were associated with CIDP refractory to IV immunoglobulin but responsive to rituximab, and some of these patients had an acute onset resembling GBS. NF186 IgG and IgM to either isoform were less specific. A severe form of CIDP, approaching a locked-in state, was seen in a patient with antibodies recognizing all 3 neurofascin isoforms. CONCLUSIONS: Neurofascin antibodies were 4 times more frequent in autoimmune neuropathy samples compared to genetic neuropathy controls. Persistent IgG4 responses to NF155 correlated with severe CIDP resistant to usual treatments but responsive to rituximab. IgG4 antibodies against the common domains shared by glial and axonal isoforms may portend a particularly severe but treatable neuropathy. The prognostic implications of neurofascin antibodies in a subset of idiopathic neuropathy patients and transient IgM responses in GBS require further investigation.
引用
- Burnor E, Yang L, Zhou H, et al. Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies. Neurology. 2017. PMID: 29187518. doi:10.1212/WNL.0000000000004773
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。